Guillem Argiles, MD

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer (CRC).

There is an important role for immunotherapy in the hyper-mutant population of patients with CRC, says Argiles.

As of now, pembrolizumab (Keytruda) is approved in the United States for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors.

Videos

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer.

Dr. Argiles Discusses the Role of Immunotherapy in CRC

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

In a study of patients with metastatic colorectal cancer, the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody was evaluated as a monotherapy and in combination with atezolizumab (Tecentriq).

Results showed evidence of antitumor activity during dose escalation with CEA-TCB monotherapy, and a manageable safety profile was observed with the atezolizumab combination as well.

Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.

Guillem ArgilÃ©s, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Author | Guillem Argiles, MD

Articles

Dr. Argiles Discusses the Role of Immunotherapy in CRC

Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

Dr. ArgilÃ©s on BRAF-Mutations in Colorectal Cancer